SAN MATEO, Calif., July 8 After meeting on July 1st and2nd an FDA advisory panel recommended that all new diabetes drugs shouldundergo trials to rule out cardiovascular risk. 85% of US cardiologists and65% of US endocrinologists agree with this recommendation, according toAlphaDetail Inc., a leader in cardiovascular and metabolic primary marketresearch and key opinion leader mapping solutions to the Global Life SciencesIndustry.
On July 3rd AlphaDetail launched its latest AlphaPulse(TM) survey tomeasure immediate physician awareness and reactions to the panelrecommendation. In a brief on-line survey of 52 cardiologists and 51endocrinologists AlphaDetail found:
To learn more about this study, please contact Bob Latshaw [email protected]
or (215) 259-5601.
About AlphaDetail, Inc.:
At AlphaDetail, we have an unparalleled commitment to our clients. We area full-service primary market research firm, with a particular emphasis inlarge and complex quantitative studies for the global healthcare community.AlphaDetail is built on one of the industry's strongest foundations thatincludes a large team of exceptional analytical specialists, the industry'sleading technology platform and a flexible approach to research that helps usanswer our client's most challenging questions.-- Unaided, about 40% of physicians mentioned CV risk associated with diabetes medications as the most important development in diabetes treatment from the past month. -- When prompted, half of physicians indicated they had heard about the FDA panel recommendation to require cardiovascular safety trials for new diabetes medications -- only a day after the news was announced. -- Although most physicians from both specialties support the recommendation, twice as many cardiologists (33%) vs. endocrinologists (16%) agree strongly with it. -- However, 22% of endocrinologists disagree with the recommendation primarily because they believe it would stifle innovation and delay the availability of important new therapies. -- Physicians disagree on the most appropriate implementation of the FDA panel recommendation -- two CV safety trials vs. only one trial. -- However, more physicians believe that the two trial implementation is the most appropriate. -- Even so, a segment of physicians (25% of cardiologists and 37% of endocrinologists) would support prescribing a new diabetes therapy that is highly efficacious but has CV risk to patients that have no CV risk factors other than diabetes. -- Physicians have to make a trade-off between controlling diabetes and preventing other diabetes complications vs. preventing CV risk.
SOURCE AlphaDetail, Inc.